Share Issue/Capital Change • Oct 10, 2012
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
Leiden, The Netherlands, October 10, 2012. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that its number of outstanding shares has increased by 11,107,078 from 888,553,129 on September 26, 2012 to 899,660,207 as of today.
The increase in outstanding shares reflects the exercise of 11,107,078 warrants out of a total 34,717,484 warrants issued to investors which participated in the €8.4 million private convertible bond announced on December 23, 2011. Cash proceeds of the warrants exercised amount to €154,000.
Pharming Group NV is developing innovative products for the treatment of unmet medical needs. Ruconest® is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum (OMX: SOBI). Ruconest® is partnered with Santarus, Inc (NASDAQ: SNTS) in North America where the drug is undergoing Phase III clinical development. The product is also being evaluated for follow-on indications in the areas of transplantation and reperfusion injury. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products. A feasibility study, using the validated transgenic rabbit platform, aimed at the development of recombinant Factor VIII for the treatment of Haemophilia A is underway with partner, Renova Life, Inc. Additional information is available on the Pharming website, www.pharming.com. To download the Pharming Group Investor Relations App, click here.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.
Sijmen de Vries, CEO: T: +31 (0)71 524 7400
FTI Consulting Julia Phillips/ John Dineen, T: +44 (0)207 269 7193
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.